이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

안전성과 면역원성을 위한 COVID-19 백신의 믹스 앤 매치 (MOSAIC)

2026년 11월 8일 업데이트: Canadian Immunization Research Network

Immunogenicity and Adverse Events After Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: 두 번째 용량(MOSAIC-1;CT24a)과 세 번째 용량(MOSAIC-2;CT24b)의 "혼합"은 안전하고 면역원성입니다. ?

The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

For dose 1 and 2, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) are two dose vaccines which were studied in schedules of either 0 and 21 days or 0 and 28 days, respectively. The ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine is authorized to be given in two doses one month to 12 weeks apart. We will compare the interval 0, 28 days to a 0, 112 days (16 weeks) schedule, and assess the immunogenicity of both heterogeneous and heterologous second doses using the Canadian schedule.

For dose 3, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and plant-based virus-like particle (Medicago Covifenz) are anticipated to be administered 6 months apart. We will assess the immunogenicity of both heterogeneous and heterologous third doses using the Canadian schedule.

For dose 4, the currently available mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) and plant-based virus-like particle (Medicago Covifenz) are anticipated to be administered 3 months apart. We will assess the immunogenicity of both heterogeneous and heterologous third doses using the Canadian schedule.

연구 유형

중재적

등록 (실제)

669

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • British Columbia
      • Kamloops, British Columbia, 캐나다
        • Royal Inland Hospital
      • Penticton, British Columbia, 캐나다
        • Penticton Regional Hospital
      • Vancouver, British Columbia, 캐나다, V5Z 4H4
        • BC Children's Hospital Research Institute
    • Manitoba
      • Winnipeg, Manitoba, 캐나다
        • Children's Hospital Research Institute of Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다
        • Canadian Center for Vaccinology
    • Ontario
      • Ottawa, Ontario, 캐나다
        • Ottawa Hospital Research Institute, University of Ottawa
    • Quebec
      • Montreal, Quebec, 캐나다, H9H 4Y6
        • McGill University Health Centre Vaccine Study Centre
      • Québec, Quebec, 캐나다
        • CHU de Québec, Université Laval

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Participant is willing and able to give written informed consent to participate in the study
  2. Age 18 years of age or older in good health or with mild or moderate stable co-morbidities at the time of enrolment
  3. Able and willing to complete all the scheduled study procedures during the whole study follow-up period
  4. If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the final dose of study vaccine (Please refer to the definition section for a description of child-bearing potential and adequate contraception)
  5. MOSAIC-1 Vaccine-exposed subgroups: have received or are booked to receive the first dose of an authorized COVID-19 vaccine in the 55 days prior to Visit 1 (documentation of receipt required)
  6. MOSAIC -1 Vaccine naïve subgroups: have not received an authorized COVID-19 vaccine at any time
  7. MOSAIC-2 participants have received two doses of COVID-19 vaccines authorized in Canada ≥6 months prior to study vaccine administration (documentation of receipt required)
  8. MOSAIC-3 participants have received three doses of COVID-19 vaccines authorized in Canada ≥3 months prior to study vaccine administration (documentation of receipt required)

Exclusion Criteria:

  1. Inability or unwillingness of participant or legally acceptable representative to give written informed consent
  2. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids
  3. Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin)
  4. Administration of immunoglobulins and/or any blood products within 3 months preceding the first dose of study vaccine and for one month after the last dose of study vaccine
  5. Allergy to any study vaccine or any active substance in a study vaccine
  6. Bleeding disorder or history of significant bleeding following IM injections or venipuncture
  7. Continuous use of anticoagulants
  8. A history of anaphylaxis to a previous vaccine
  9. Pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine
  10. MOSAIC-1: History of laboratory-confirmed COVID-19 disease prior to enrolment by participant report
  11. Administration of a live virus vaccine within 4 weeks prior to study vaccine receipt.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Group 1: Moderna, Moderna - 28 Days apart

Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 28 days post first injection

활성 비교기: Group 2: Moderna, Moderna - 112 days apart

Participants will be blinded and receive two doses (0.20 mg/mL each) of mRNA-1273 SARS-CoV-2 vaccine at 0.20 mg/mL via intramuscular injection in the deltoid muscle 112 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 112 days post first injection

활성 비교기: Group 3: Moderna, Pfizer/BioNTech - 28 days apart

Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 4: Moderna, Pfizer/BioNTech - 112 days apart

Participants will be blinded and receive one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3mL) of BNT162b2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 5: Pfizer/BioNTech, Pfizer/BioNTech - 28 days apart

Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 28 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 days apart

Participants will be blinded and receive two doses (0.3mL each) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle 112 days apart.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 7: Pfizer/BioNTech, Moderna - 28 days apart

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 8: Pfizer/BioNTech, Moderna - 112 days apart

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 9: Astra Zeneca, Moderna - 28 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 28 days post first injection

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

다른 이름들:
  • 박제브리아
  • 아스트라제네카 코로나19 백신
  • COVISHIELD AstraZeneca COVID-19 백신
활성 비교기: Group 10: Astra Zeneca, Moderna - 112 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.20 mg/mL) of mRNA-1273 SARS-CoV-2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

Second injection administered 112 days post first injection

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

다른 이름들:
  • 박제브리아
  • 아스트라제네카 코로나19 백신
  • COVISHIELD AstraZeneca COVID-19 백신
활성 비교기: Group 11: Astra Zeneca, Pfizer/BioNTech - 28 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 28 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 28 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

다른 이름들:
  • 박제브리아
  • 아스트라제네카 코로나19 백신
  • COVISHIELD AstraZeneca COVID-19 백신
활성 비교기: Group 12: Astra Zeneca, Pfizer/BioNTech - 112 days apart

Participants will be blinded and receive one dose (0.5 ml) of ChAdOx1-S [recombinant] vaccine via intramuscular injection in the deltoid muscle followed by one dose (0.3 mL) of BNT162b2 vaccine after 112 days.

Vaccine-exposed participants will only be blinded to, and receive, the second injection.

Second injection administered 112 days post first injection

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신

A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).

다른 이름들:
  • 박제브리아
  • 아스트라제네카 코로나19 백신
  • COVISHIELD AstraZeneca COVID-19 백신
활성 비교기: Group 1b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 2b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나
활성 비교기: Group 3b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나
활성 비교기: Group 4b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 5b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나
활성 비교기: Group 6b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 7b

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 8b

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나
실험적: Group 9b

Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

다른 이름들:
  • 메디카고 COVID-19 백신
활성 비교기: Group 1c

Participants will be blinded and receive one dose (0.3mL) of BNT162b2 vaccine via intramuscular injection in the deltoid muscle.

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 2c

Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

다른 이름들:
  • 메디카고 COVID-19 백신
활성 비교기: Group 3c

Participants will be blinded and receive one half dose (0.25mL) of mRNA-1273 vaccine via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나
활성 비교기: Group 4c

Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

다른 이름들:
  • 메디카고 COVID-19 백신
활성 비교기: Group 5c

Participants will be blinded and receive either one dose (0.3mL) of BNT162b2 or one half dose (0.25mL) of mRNA-1273 via intramuscular injection in the deltoid muscle.

Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.

다른 이름들:
  • 스파이크백스
  • 코로나19 백신 모더나

A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.

다른 이름들:
  • 동호회
  • 화이자-BioNTech COVID-19 백신
활성 비교기: Group 6c

Participants will be blinded and receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

다른 이름들:
  • 메디카고 COVID-19 백신
실험적: Group 7c

Participants will receive one dose (0.5mL) of Covifenz vaccine via intramuscular injection in the deltoid muscle.

COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration

다른 이름들:
  • 메디카고 COVID-19 백신

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Antibody response to SARS-CoV-2 S protein after 2 doses
기간: Day 56

The co-primary outcome for the non-inferiority comparison of 0, 28-day schedules with heterologous second dose is the immune response to SARS-CoV-2 at day 56 (28 days after the second dose of vaccine) based on anti-spike antibody titers.

Day 56
Antibody response to SARS-CoV-2 S protein after 2 doses
기간: Day 140

The co-primary outcome for the non-inferiority comparison of schedules in which the timing of the second dose of vaccine is different (0, 28 days v 0, 112 days) is the immune response to SARS-CoV-2 at day 140 (28 days after the last dose in the 0, 112 day schedule) based on anti-spike antibody titers.

Day 140
Antibody response to SARS-CoV-2 S protein after 3 doses
기간: Day 28

To determine if a vaccination schedule with a heterologous third dose of a COVID-19 vaccine induces a non-inferior serum immune response to SARS-CoV-2, compared to a third dose/booster with a homologous vaccine.

Day 28
Antibody response to SARS-CoV-2 S protein after 4 doses
기간: Day 28

To determine if a vaccination schedule with a heterologous fourth dose of a COVID-19 vaccine induces a non-inferior serum immune response to SARS-CoV-2, compared to a third dose/booster with a homologous vaccine.

Day 28

2차 결과 측정

결과 측정
측정값 설명
기간
Durability of antibody response to SARS-CoV-2 S over 12 months after 2 doses
기간: Baseline and Days 28, 56, 112, 140, 365

Assess durability of immune responses in each study group over 12 months based on anti-spike antibody titers and pseudoneutralization assay.

Baseline and Days 28, 56, 112, 140, 365
Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity (ADCC), Antibody avidity, RNA seq after 2 doses
기간: Days 28, 56, 112, 140, 365

Characterization of the immune response to COVID-19 vaccines in schedules with 0, 28 days versus 0, 112 days dosing and heterologous schedules to day 365.

Days 28, 56, 112, 140, 365
Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 2 doses
기간: From time of first study injection through Day 365.

Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

From time of first study injection through Day 365.
Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 3 doses
기간: From time of first study injection through Day 365.

Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

From time of first study injection through Day 365.
Acceptability of vaccines as determined by participant-completed questionnaire after 2 doses
기간: Days 56, 140, and 365

Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.

Days 56, 140, and 365
Acceptability of vaccines as determined by participant-completed questionnaire after 3 doses
기간: Days 28, 180

Four 5 point likert scale type questions asking whether they would want to receive the vaccine again, recommend it to a friend, whether they were anxious about receiving it, and whether they would prefer a more painful injection if it conferred better protection.

Days 28, 180
Antibody to SARS-CoV-2 S and N, RBD after 3 doses
기간: Days 180 and 365

Assess durability of the immune responses in each study group over 12 months after the study vaccine.

Days 180 and 365
Pseudoneutralization assay, T cell testing, Antibody dependent cellular cytotoxicity after 3 doses
기간: Day 365

Further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365
Incidence of grade 3 solicited local and systemic adverse events, SAEs, AEFIs, MAAEs, AESIs in the 7 days following vaccine receipt after 4 doses
기간: From time of first study injection through Day 365.

Description of safety outcomes over 12 months post-vaccination including SAEs (serious adverse events), provincially reportable AEFIs (adverse events following immunization), MAAEs (medically attended adverse events), AESIs (adverse events of special interest).

From time of first study injection through Day 365.
Acceptability of vaccines as determined by participant-completed questionnaire after 4 doses
기간: Days 28, 180

Four 5 point likert scale type questions asking whether they would want to receive the vaccine again(Yes, definitely; Yes, probably; I don't know; No, probably not; No, definitely not), recommend it to a friend(Yes, definitely; Yes, probably; I don't know; No, probably not; No, definitely not), whether they were anxious about receiving it(Not at all; A little; Moderately; Very; Extremely), and whether they would prefer a more painful injection if it conferred better protection(Vaccine A; Vaccine B; No preference; Unsure/don't know).

Days 28, 180
Antibody to SARS-CoV-2 S and N, RBD after 4 doses
기간: Days 180 and 365

Assess durability of the immune responses in each study group over 12 months after the study vaccine.

Days 180 and 365
Antibody dependent cellular cytotoxicity after 4 doses
기간: Day 365

Further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365
Pseudoneutralization assay after 4 doses
기간: Day 365

Measuring the 50% Neutralization Titer to further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365
T cell testing after 4 doses
기간: Day 365

Measuring the number of T cells to further characterize the immune response to COVID-19 vaccine in schedules with homologous and heterologous third doses to day 365

Day 365

기타 결과 측정

결과 측정
측정값 설명
기간
Exploratory assessment of interval between dose 1 and 2 on immune response after 3 or 4 doses
기간: From time of first study injection through Day 365.

Assess the role of intervals between first and second doses of the primary immunization schedule, and between 2nd and 3rd doses, on immune responses after the third dose over the study period.

From time of first study injection through Day 365.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Joanne Langley, Dalhousie University/CIRN

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 6월 11일

기본 완료 (실제)

2022년 7월 25일

연구 완료 (실제)

2023년 6월 16일

연구 등록 날짜

최초 제출

2021년 5월 18일

QC 기준을 충족하는 최초 제출

2021년 5월 19일

처음 게시됨 (실제)

2021년 5월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 8일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .